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Summary: Apolipoprotein E is one of the apolipoproteins involved in cholesterol metabolism. Three major isoforms
are present in men: E2, E3, E4 corresponding to the products of three alleles. They have different affinities for
receptors and the ε4 allele is a risk factor for cardiovascular diseases and more recently for Alzheimer's disease.
We describe here the production, by heterologous expression in Escherichia coli, of the three apolipoprotein Ε
isoforms for use in both research and clinical laboratories. By Surface Plasmon Resonance, the purified recombinant
apolipoprotein Ε isoforms were able to recognize three monoclonal anti-human apolipoprotein Ε antibodies with
affinity constants close to those of purified human apolipoprotein E. For receptor binding studies, the recombinant
apolipoprotein Ε isoforms were associated with VLDL isolated from apolipoprotein Ε knockout mice. Although
the association of the recombinant apolipoproteins Ε with the mouse VLDL was less efficient than that of human
plasma apolipoprotein E3, the recombinant apolipoprotein E3 and apolipoprotein E4 complexes competed efficiently
with 125I-labelled LDL for binding to the LDL receptor in J774 macrophages, whereas the recombinant apolipoprot-
ein E2-VLDL complexes did not. These results suggest that the recombinant apolipoprotein Ε isoforms have biologi-
cal properties similar to the human apolipoprotein Ε isoforms.
Introduction
Apolipoprotein Ε is a component of several classes of
lipoproteins that serve as lipid transport particles in hu-
man plasma and body fluids (1). Apolipoprotein Ε is
synthesized with an 18 amino acid signal peptide that is
cleaved cotranslationally (2). The resulting 299 amino
acid protein is a secretory glycoprotein expressed by a
variety of tissues, essentially liver parenchymal cells,
but also macrophages, adrenal glands and astrocytes in
the brain where it has been shown to be the major apoli-
poprotein (3,4). The protein is secreted in a highly sialy-
lated form but is then processed to its plasma state in
which 80% of the protein is desialylated (3).
Human apolipoprotein Ε is polymorphic. This polymor-
phism stems from three common alleles ε2, ε3 and ε4
(5). Three homozygous phenotypes (apolipoprotein
E2/E2, E3/E3 and E4/E4) and three heterozygous phe-
notypes (apolipoprotein E3/E2, E3/E4 and E4/E2) arise
from the expression of any two of the alleles. In the
Caucasian population the prevalence is: apolipoprotein
E2/E2 1%, apolipoprotein E3/E3 60%, apolipoprotein
E4/E4 3%, apolipoprotein E3/E2 12%, apolipoprotein
E3/E4 23% and apolipoprotein E4/E2 2% (6). apolipo-
protein E4 and apolipoprotein E2 differ from apolipo-
protein E3 by one of two point mutations resulting in
Cys/Arg interchanges (Cys112 —»· Arg for apolipoprotein
E4 and Arg158 —» Cys for apolipoprotein E2).
Apolipoprotein E also plays a role in immunoregulation
and is implicated in the regeneration of the sciatic nerve
where it is synthesized by macrophages (7). Apolipo-
protein E is a ligand for several receptors: the apolipo-
protein (B/E) low density lipoprotein receptor (LDL re-
ceptor), the LDL receptor-related protein (LRP), as well
as the VLDL receptor, lipolysis-stimulated receptor
(LSR) and a newly described apolipoprotein E receptor
2 (3, 8—10). The loss of Arg158 in the apolipoprotein E2
isoform results in a loss of the capacity of apolipoprotein
E to bind to the LDL receptor, and subjects developing
type III hyperlipoproteinaemia often present the ε2/ε2
phenotype (11, 12). Apolipoprotein E4 is a risk factor
for coronary diseases because of its direct increasing ef-
fect on cholesterol levels (13).
Compelling evidence has recently implicated apolipo-
protein E in the development of Alzheimer's disease
(14). There is a dose-response relationship between the
ε4 allele and the occurrence of late onset Alzheimer's
disease: ε4 homozygosity is a major risk factor for Alz-
heimer's disease (15). There is a link between apolipo-
protein E4 and early development of the disease and an
increased number of senile plaques and fibrillary depos-
its (16, 17). In contrast, apolipoprotein E2 would be a
longevity factor and seems to play a protective role in
Alzheimer's disease (18, 19).
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Because of the implication of particular apolipoprotein
E genotypes in cardiovascular or neurodegenerative dis-
eases, we reasoned that the gene product could be in-
volved and we decided to produce large quantities of
these proteins for various applications, including the
production of a reference material. Such a standard is
necessary for developing a reference method suitable in
both research and clinical laboratories worldwide.
This report describes the development of an expression
system to produce the three apolipoprotein E isoforms
in E. coli and the subsequent characterization of the re-
combinant fusion proteins. Compared to the other apoli-
poprotein E expression systems previously described in
bacteria, ours is able to produce large amounts of recom-
binant apolipoprotein E that could be easily purified.
The first one described in the literature (27) provided
some apolipoprotein E that was rapidly proteolyzed, and
more recently, another system expressing apolipoprotein
E in the periplasm (28) had a very low level of pro-
duction of the recombinant protein. The major advantage
of our expression system is the single-step purification
of the recombinant apolipoprotein E. The purification of
the recombinant protein expressed in all other expres-
sion systems, as the purification of the human plasma
apolipoprotein E, requires several Chromatographie
steps. The plasma human apolipoprotein E purification
needs the isolation of human very low density lipopro-
teins (VLDL) and several steps of delipidation before
the affinity and gel filtration chromatography. In addi-
tion our expression system overcomes the extreme diffi-
culties in obtaining more rare phenotypes in the human
population such as apolipoprotein E4 and apolipoprotein
E2. In contrast to purification after plasmapheresis, our
system permits the isolation of purified protein without
contamination with other apolipoproteins (apolipoprot-
ein B, apolipoprotein C). E. coli allowed a very rapid
inexpensive method for obtaining a high amount of re-
combinant apolipoprotein E that was purified with a
high degree of purity. We have described separately
some physicochemical properties of the recombinant
apolipoprotein E3 and apolipoprotein E4 (20).
One of our aims is to compare the different properties
of the three isoforms, particularly their conformation, to
establish the molecular basis of the difference in reactiv-
ity and/or metabolism of the three isoforms, and to
understand their involvement in neurodegenerative dis-
eases in order to elucidate the potential protective role
of apolipoprotein E2 and the role of apolipoprotein E4
as a risk factor in Alzheimer's disease.
To assess their immunological characteristics, we quan-
titatively measured the binding of three anti-human
apolipoprotein E monoclonal antibodies (21) to plasma
apolipoprotein E3 and recombinant apolipoprotein E
isoforms (apolipoprotein E2, E3 and E4) by Surface
Plasmon Resonance (SPR). Surface Plasmon Resonance
detection allows the quantitative real-time measurement
of binding interactions between immobilized and solu-
tion-phase ligands without radiolabelling or biochemical
tagging. The biological activity of the recombinant ma-
terial was also investigated by testing the LDL-receptor




Specific products were from the following suppliers: Taq DNA
polymerase from Boehringer Mannheim (Germany), [a-32P]dATP
(29.6 TBq/mmol = 800 mCi/mmol) and autoradiography films
from Dupont Nemours (USA), restriction enzymes from Boeh-
ringer Mannheim (Germany) and Promega (Madison, USA), nucle-
otides, apolipoprotein Ε-specific oligonucleotides for amplification
by polymerase chain reaction, apolipoprotein E4 and apolipoprot-
ein E2 specific oligonucleotides for mutagenesis, M13 reverse se-
quencing primer, pARHS2, 5-bromo-4-chloro-indolyl- -£)-galac-
topyranoside (XGal), and z'sopropyl- -D-thiogalactopyranoside
(IPTG) from Eurogentec (Belgium), ProBond Gel, TA cloning kit
and pRSETB from Invitrogen (San Diego, USA), E. coli
BL21(DE3) competent cells from Novagen (Madison, USA), HBS
buffer (0.010 mol/1 HEPES pH 7.4, 0.15 mol/1 Nad, 0.0034 mol/1
EDTA, 50 μΐ/ΐ surfactant P20), amine coupling kit (0.1 mol/1 N-
hydroxysuccinimide, 0.4 mol/1 N-ethyl-N'-(diethylaminopropyl)
carbodiimide and 1.0 mol/1 ethanolamine hydrochloride, pH 8.5)
were obtained from Pharmacia, Biosensor (Sweden), T7 sequenc-
ing kit and oligo (dT)i2-i8 for reverse transcription, molecular
mass markers from Pharmacia Biotech (Sweden), Altered Sites™
in vitro Mutagenesis System, M-MLV reverse transcriptase and
RNasine from Promega (Madison, USA), LB, LB agar, ampicillin,
carbenicillin, kanamycin, dimethylsulphoxide and dithiothreitol
from Sigma (Missouri, USA).
Construction of different cDNAs
The cloning of apolipoprotein E3 and apolipoprotein E4 cDNA has
been previously described (21). The apolipoprotein E2 sequence for
expression in Escherichia coli was derived by polymerase chain re-
action from the mutated sequence of apolipoprotein E2 obtained by
direct mutagenesis of the cDNA of apolipoprotein E3 and cloned into
the eukaryotic pcDNAIneo vector (Barbier, unpublished). Amplifi-
cations were from pcDNAIneo-apolipoprotein E2 using oligonucle-
otides 5 'GATCCCATGGCTAAGGTGGAGCAAGCGGTGGAG3'
as 5' primer and 5'GATCAAGCTTCAGTGATTGTCCCTGGG-
CAC3' as 3' primer (underlined sequences correspond to the restric-
tion sites Nco I and Hind III respectively). The reaction contained
15 ng pcDNAIneo-apolipoprotein E2 in 0.075 mol/1 Tris-HCl pH
9.0, 0.020 mol/1 (NH4)2SO4, 100 mg/1 Tween 20 buffer supple-
mented with 0.002 mol/1 MgCl2, 0.2 mmol/1 of each dNTP, 0.001
mmol/1 of each primer, 50 ml/1 dimethylsulphoxide, 2 U Taq DNA
polymerase. After an initial denaturation step for 6 minutes at 96 °C,
amplification was achieved with the following program: l min at
96 °C, 2 min at 60 °C, 3 min at 72 °C, 16 cycles. The PCR product
was first cloned in the pCRII vector using the TA cloning kit. The
integrity of these new sequences was confirmed by DNA sequenc-
ing. The cDNAs were then subcloned in pRSETB expression vectors
between Nco I/Hind III restriction sites from which they were reco-
vered by Nde IIHind III restriction digestion and subsequent cloning
into the same sites of the modified pARHS2 vectors.
Bacterial expression systems
The pRSETB vector allows the cytoplasmic expression of the com-
plete apolipoprotein E sequence in fusion with a Mr 4000 ammo-
terminal peptide that contains a poly-His stretch. This plasmid is
under the control of the strong T7 promoter.
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pARHS2 expresses the same protein as pRSETB. This very stable
plasmid is under the control of the T7 promoter and contains the
hok/sok system (hok - host killing, sok — suppression of killing),
which leads to cell death for plasmid free cells.
For the expression of the apolipoprotein E sequence pRSETB-apo-
lipoprotein E3 and pARHS2-apolipoprotein E3, -apolipoprotein E2
and -apolipoprotein E4 need to be introduced into an E. coli (DE3)
strain (F~, ompTri, mg, λ(ΟΕ3)) (22) that carries the T7 RNA
polymerase gene under the control of the lacUVS promoter. The
BL21 E. coli strain provides an excellent background for expres-
sion of recombinant protein since it lacks Ion and ompΤ proteases.
Stability of the expression vectors
To study the stability of the recombinant plasmid, DE3 lysogens
that carried the plasmid conferring ampicillin resistance were tit-
ered on four plates containing 0.1 g/1 ampicillin, 0.001 mol/1 iso-
propyl- -D-thiogalactopyranoside (IPTG), both or neither. The
plasmid stability was followed throughout the production: saturated
primary culture, t0: time of induction, to + 1 h, t0 + 3 h, to + 5 h:
one hour, three hours and five hours after induction respectively
and one growth curve for the E. coli strain was established. One
ml of culture was diluted to an Aeoo of 10~5, then 50 μΐ were plated
on four different plates containing 0.1 g/1 ampicillin, or 0.001 mol/1
zsopropyl- -D-thiogalactopyranoside (IPTG) or both or with nei-
ther component. The percentage of cells on the plate/number of
viable cells was calculated.
Production and purification
E. coli BL21(DE3) strains carrying pRSETB-apolipoprotein E3,
pARHS2-apolipoprotein E3, pARHS2-apolipoprotein E2 or
pARHS2-apolipoprotein E4 were grown overnight at 37 °C in Lu-
ria-Bertani (LB) medium containing 0.1 g/1 ampicillin and then
diluted 100-fold into LB-ampicillin medium and grown to a cell
density A600 of 0.6. Then 0.001 mol/1 wopropyl- -Z)-thiogalacto-
pyranoside (IPTG) was added and the culture was grown further
for 2 to 24 hours. Bacteria from 1 litre of culture were harvested
by centrifugation (1000g, 10 min, + 4 °C) and the pellet was re-
suspended in 40 ml of 0.02 mol/1 Tris-HCl, 0.1 mol/1 NaCl. Lyso-
zyme (15 g/1 in H2O) was added to a final concentration of 0.75
g/1 and the sample was incubated at room temperature for 30 min-
utes. Cells were lysed by sonication (5 bursts, 40 W, 10 s/burst) on
ice. RNase and DNase were added to a final concentration of 0.001
g/1 and 0.025 g/1, respectively, and the sample was incubated for
30 min at room temperature. After centrifugation (20000 g, 15 min,
+ 4 °C) the pellet was resuspended in 40 ml of 0.020 mol/1 Tris-
HCl, 0.1 mol/1 NaCl containing 1 g/1 Triton X-100 and stirred at
room temperature for 30 min. Insoluble material was removed by
centrifugation (20000g, 15 min, + 4 °C) and the soluble proteins
were precipitated by addition of acetone (final volume fraction 0.6)
and recovered by centrifugation (20000g, 15 min, + 4 °C). The
pellet was resuspended in 40 ml of 6 mol/1 guanidine-HCl, 0.20
mol/1 sodium phosphate buffer pH 7.8, 0.5 mol/1 NaCl and stirred
overnight at + 4 °C. After centrifugation (20000g, 15 min,
+ 4 °C), the supernatant was filtered through a 0.22 μιη filter and
loaded on a Ni-Gel (ProBond gel) column that was previously
equilibrated with a 0.20 mol/1 phosphate buffer at pH 7.8 contain-
ing 6 mol/1 urea, 0.15 mol/1 NaCl. Two washing steps were per-
formed: first with the equilibration buffer pH 7.8 to remove un-
bound material, then with the same buffer at pH 6.0. The elution
was finally performed with the same buffer at pH 4.O. The fractions
were dialyzed extensively against 0.1 mol/1 ammonium bicarbon-
ate, aliquoted and stored at — 80 °C.
Human apolipoprotein E3 was purified from human plasma very
low density lipoproteins of normal ε3/ε3 individuals as previously
described (23).
Characterization of recombinant human
apolipoprotein E isoforms by Surface Plasmon
Resonance analysis
The analysis was performed on a BIAlite™ apparatus (Pharmacia
Biosensor, Sweden) using Surface Plasmon Resonance (24). Sur-
face Plasmon Resonance uses an optical method to detect changes
in the refractive index within a thin dextran matrix. The binding
of a soluble protein to an immobilized ligand increases the protein
concentration within the matrix. This alters the refractive index
within the matrix and this change is quantified in resonance units
(R. U.). The response directly correlates with the bound ligand
mass.
Preparation of the sensorchip surface
During immobilization, the flow rate was maintained at 5 μΐ/min.
The surface of the CM5 sensorchip was activated by injecting 35 μΐ
of a mixture of 0.1 mol/1 N-ethyl-N'-(diethylaminopropyl)carbodii-
mide/0.4 mol/1 N-hydroxysuccinimide (1 + 1 by vol.). Then 35 μΐ
of 0.01 g/1 apolipoprotein E in 0.01 mol/1 sodium acetate (pH 4.0)
were injected followed by 20 μΐ of 4 mol/1 guanidine-HCl, 0.01
mol/1 Tris, pH 8.0. The surface was saturated by injection of 35 μΐ
of 1.0 mol/1 ethanolamine hydrochloride, pH 8.5. This method im-
mobilizes the ligand via the primary amino groups. Since 1000
resonance units (R. U.) determined by Surface Plasmon Resonance
correspond to 1.0 pg/mm2 of bound ligand, the total immobilized
mass of apolipoprotein E under these conditions was: human
plasma apolipoprotein E3 = 7.5 pg/mm2, recombinant apolipoprot-
ein E3 = 3.53 pg/mm2, recombinant apolipoprotein E4 = 4.5 pg/
mm2, recombinant apolipoprotein E2 = 4.45 pg/mm2.
Kinetic analysis of monoclonal antibody binding to
apolipoprotein E
Stock solutions of each of the antibodies were diluted in running
buffer (HBS buffer, see "Materials") to a final concentration of
40—1000 nmol/1. For the binding experiments 20 μΐ of antibody
were injected at a constant flow rate of 5 μΐ/min (contact time
- 4 min). The antigen/monoclonal antibody dissociation was fol-
lowed for 5 min. The sensorchip surfaces were regenerated with
2 mol/1 of formic acid (14 to 20 μΐ, depending on the experiment).
Data for the association and the dissociation phases were collected
and evaluated to determine the association and dissociation rate
constants with the Biaevaluation 2.1 software provided by the man-
ufacturer (25). All determinations were performed at 25 °C.
A kinetic analysis of the sensorgrams obtained from the interaction
of a monoclonal antibody with an immobilized apolipoprotein E
was based on the following equation (25):
dR/dt = fcass C Rmax - (k^ C + £diss) R (Eq. 1)
where
R is the plasmon resonance-response unit (R. U.) due to the interac-
tion of the monoclonal antibody with apolipoprotein E in the sur-
face,
A:ass and £diss are the association (1 · mol"1 · s"1) and dissociation
(s~') rate constants, respectively,
C is the molar concentration of injected monoclonal antibody and
Rmax is the R. U. response at saturation of the apolipoprotein E
binding sites.
It can be shown that &ass may be determined from the association
phase of the sensorgram, i. e., the slope of a plot of monoclonal
antibody concentration versus the slopes (called &s) of dR/dt depen-
dence on R. U. response (25). A second possibility for determining
£ass is to first calculate A:diss and then to resolve equation (1), which
has now become a first order equation with one unknown value.
Values for £diss can be calculated during the dissociation phase of
the sensorgram since as C —»zero, the decay rate (—dR/dt) gives
£diss directly.
LDL-receptor binding
Isolation and enrichment of VLDL
Apolipoprotein E deficient VLDL were isolated by density gradient
ultracentrifugation from the serum of apolipoprotein E knockout
mice. Purified recombinant or purified human apolipoprotein E
were incubated with apolipoprotein E deficient VLDL (0.2 g/g
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apolipoprotein E deficient VLDL protein) for I hour at 37 °C. The
volume was corrected with phosphate buffered saline. Apolipoprot-
ein E enriched VLDL were separated from free apolipoprotein E by
another ultracentrifugation step. Control apolipoprotein E deficient
VLDL were treated identically. After centrifugation, protein and
apolipoprotein E contents were determined and the VLDL were
stabilized with 10 g/1 of bovine serum albumin.
Cell and LDL receptor binding studies
J774 Macrophages were grown in 24-well culture plates with Dul-
becco's Modified Eagle Medium/fetal calf serum, volume fraction
0.1. Twenty hours before the experiment, the medium was changed
to Dulbecco's Modified Eagle Medium/50 ml/1 lipid free human
serum. Incubations were performed for 3 hours on melting ice in
tetraplot in Dulbecco's Modified Eagle Medium/10 g/1 human se-
rum albumin. [125I]LDL (0.01 g/1) competed with either the respec-
tive non-labelled (apolipoprotein E enriched) apolipoprotein E defi-
cient VLDL or with non-labelled LDL (0-0.05 g/1). After incuba-
tion, cells were washed 5 times with phosphate buffered saline/
1 g/1 bovine serum albumin and once with phosphate buffered sa-
line alone. Cells were dissolved in 1 ml of 0.2 mol/1 NaOH. Seven-
hundred of the suspension was used for measurement of radioac-
tivity, while 100 was used for cell protein measurements. The
binding expressed as a percentage of the control (without competi-
tor) was plotted against the amount of competitor.
Results
Expression vector stability and recombinant
apolipoprotein production
To study the stability of the different vectors in the E.
coli BL21(DE3) strain and to ascertain whether apolipo-
protein production was lethal to the cells, we titered
bacteria following zsopropyl-ß-D-thiogalactopyranoside
induction on four different media: LB and LB contain-
ing ampicillin. wopropyl-ß-D-thiogalactopyranoside, or
both. Assuming that recombinant apolipoprotein E is
toxic,
a) all viable cells would grow on the plate without any
additive;
b) only cells that retained the plasmid would grow in
the presence of ampicillin;
c) only cells that had lost plasmid or mutants that had
lost the ability to express the apolipoprotein E gene
would grow in the presence of z'sopropyl-ß-D-thiogalac-
topyranoside,
d) finally, only mutants that had lost the ability to ex-
press the apolipoprotein E gene would grow in the pres-
ence of both ampicillin and wopropyl-ß-ZMhiogalacto-
pyranoside.
When cultures of E. coli BL21(DE3)-pRSETB apolipo-
protein E were induced by wopropyl-ß-Z)-thiogalacto-
pyranoside, inconsistent and non-reproducible results
were observed:
a) cell death immediately after induction characterized
by total plasmid loss and no production;
b) partial loss of the plasmid with slow growth of the
remaining cells and low production level;
c) no loss of plasmid with slow cell growth and high
production level (fig. 1). In addition, the preservation at
—80 °C of isolated producing clones resulted in a loss
of production capability.
In view of these results the cDNAs of apolipoprotein E
were subcloned into the pARHS2 expression vector.
This plasmid contains the parB locus, which enhances
vector stability.
The stability of the recombinant pARHS2 expression
vector was studied throughout the culture. We observed
that after induction by zsopropyl-ß-£)-miogalactopyrano-
side, all viable cells harboured the recombinant vector
(results not shown). This vector stability and the con-
comitant high level production of recombinant protein
induced a decrease in the growth rate. After induction
with zsopropyl-ß-Z)-thiogalactopyranoside, recombinant
E. coli BL21(DE3) cells specifically produced a protein
with a MT of 40 000, in accordance with the theoretical
relative molecular mass of the recombinant apolipoprot-
ein E. This protein reacted strongly upon immunoblot-
ting with monoclonal anti apolipoprotein E antibodies,
thus confirming its authenticity (fig. 2b). The production
level increased during the first 5 hours of induction
(figs. 2a, 2b) reaching about 80 mg/1 (25% of total cell
protein) as estimated by scanning of the gels. After 24
hours (fig. 2a, lane 9) the production level was much
lower, probably due to cell lysis as no degradation pro-
ducts were visible upon immunoblotting. There were no
differences in the production level and the immunologi-
cal reactivity of the apolipoprotein E expressed in this
system. Furthermore all producing clones were stable
upon conservation at —80 °C. These results suggested
that the production of recombinant human apolipoprot-
ein E is not lethal to the cells when the pARHS2 vector
is used.
Recombinant human apolipoproteins E were purified by
Ni2+-chelating affinity chromatography as previously
described (20). The conditions for the solubilization of
the bacterial proteins have changed in order to insure a
better yield of purified protein. Determination of the
first eight amino acids showed that the sequence corre-
sponded to that predicted from the vector sequence.
Characterization of recombinant
apolipoproteins E
Monoclonal antibody-apolipoprotein E interactions
studied by Surface Plasmon Resonance
In order to confirm that the immunological properties
of the recombinant apolipoproteins E were intact, each
protein was tested for binding to several anti-human
plasma apolipoprotein E monoclonal antibodies.
To analyze the interaction of monoclonal antibodies
3B7, 1D7 and 3H1 with apolipoprotein E isoforms,
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Fig. l Stability of the pRSETB-apolipoprotein E3 plasmid after
induction by zsopropyl-ß-D-thiogalactopyranoside.
The protein was produced by the BL21(DE3) E. coli strain in Lu-
ria-Bertani (LB) medium containing 0.1 g/1 ampicillin. After dif-
ferent times of induction with 0.001 mol/1 z-sopropyl-ß-D-thiogalac-
topyranoside, aliquots were diluted to an A60o = 10~5. Fifty of
diluted aliquots were grown overnight on LB, LB-ampicillin, LB-
wopropyl-ß-Z)-thiogalactopyranoside and LB-ampicillin-wopropyl-
ß-D-thiogalactopyranoside agar medium. Stability was calculated
from the percentage of ampicillin-resistant colonies. The studies of
the stability of the recombinant vector pRSETB-apolipoprotein E
in E. coli strain showed several behaviours of this plasmid in dif-
ferent clones during the culture:
a) very fast total plasmid loss (—A—),
b) partial plasmid loss (--·—) and
c) no loss of the plasmid (··>···)·










Fig. 2 Time course of the recombinant apolipoprotein E3 pro-
duction with the expression plasmid pARHS2 in BL21(DE3)
strain.
Total lysate from non-induced and induced cultures prepared by
solubilization of the cell pellets in denaturing buffer (Sambrook et
al. 1989) by heating in a boiling water bath for 3 min. Equivalent
quantities of cells were loaded on a SDS-PAGE 0.1% SDS, 12%
polyacrylamide gel.
a) Proteins were stained in Coomassie Brilliant Blue. Pharmacia
low molecular mass standards are shown in lane 1. Lane 2: sample
at to (no induction); lane 3, 4, 5, 6, 7, 8, 9: samples at t0 + 30
apolipoprotein E isoforms (recombinant human apolipo-
protein E3, apolipoprotein E2, and apolipoprotein E4
purified from E. coli and human plasma apolipoprotein
E3) were immobilized on separate sensorchips by cou-
pling via primary amine groups. The binding of the mo-
noclonal antibodies to apolipoprotein E was measured
by Surface Plasmon Resonance and the affinity and ki-
netic determinations were estimated using the Biaevalu-
ation 2.1 software. As shown in figure 3a, recombinant
apolipoproteins E bound with high affinity to the mo-
min, + 1 h, + 2 h, + 3 h, + 4 h, + 5 h, + 24 h after induction by
wopropyl-ß-D-thiogalactopyranoside. The arrow indicates apolipo-
protein E.
b) The proteins from a gel equivalent to a were transferred to an
Immobilen P membrane. Immunoblotting was performed with anti-
human apolipoprotein E monoclonal antibody 1D7 and alkaline
phosphatase labelled anti-mouse IgG.
Lane 1: sample at to (no induction); lane 2, 3, 4, 5, 6, 7, 8: samples
at to + 30 min, + l h, + 2 h, + 3 h, + 4 h, + 5 h, + 24 h after
induction by zsopropyl-ß-D-thiogalactopyranoside. The arrow indi-
cates apolipoprotein E.
noclonal antibodies, and these interactions were satura-
ble and reversible. Figure 3b shows that the relation be-
tween the ks and the monoclonal antibody concentration
is linear. These results indicate that the observed signals
increase proportionally with the monoclonal antibody
concentration thus allowing the estimation of kinetic
constants. Table 1 summarizes the rate constants and the
equilibrium dissociation constants (&ass, k^ss, KO) for the
apolipoprotein -antibody interactions. &ass is the mean
of the kass values defined using both methods (with
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Fig. 3 Surface Plasmon Resonance analysis of the interaction be-
tween purified recombinant apolipoprotein E3 and monoclonal an-
tibody 3H1.
a) Binding of monoclonal antibody (3H1) to purified recombinant
apolipoprotein E3. The binding was measured as the increase in
resonance units (R. U.). Curves a, b, c, d: [monoclonal antibody
3H1] = 30 nmol/1; 60 nmol/1; 100 nmol/1 and 220 nmol/1, respec-
tively.
b) Linear curve ks versus monoclonal antibody concentration. In
figure 3 a, the association phase was graphed (dR/dt) as a function
of binding (R. U.), ks was calculated as to be the slope of this
graph. Then &ass was determined by plotted ks versus monoclonal
antibody concentration.
Slope = kass.
and without calculation of ks). The results showed that
the three monoclonal antibodies recognized the three
recombinant apolipoprotein E isoforms similarly to
plasma human apolipoprotein E3 and with close ki-
netic characteristics.
LDL receptor binding studies
The LDL receptor binding activity of the recombinant
apolipoproteins E was assessed using the J774 macro-
phage cell line. VLDL from apolipoprotein E knockout
mice were separately enriched with each of the recombi-
Tab. 1 Kinetic constants of the interaction between three monoclonal anti-apolipoprotein E antibodies







l· ·"•assa = 5.03 ± 0.42
b = 1.18 ± 0.42
; = 2.35 ± 1
kass = 4.34 ± 0.2
kdiss = 2.66 ± 0.68
KO = 6.13 ± 1.40
Kass
^ass
= 3.5 ± 0.45
= 2.28 ± 1.1
= 6.51 ± 3.90
= 3.29 ± 0.36
, = 2.18 ±0.37




- 10.5 ± 0.69
5 = 2.13 ±0.25
= 2.02 ± 0.21
kass = 6.21 ± 0.61
kdiss = 2.25 ± 0.06





= 5.28 ± 1.5
,= 1.34 ±0.20
= 2.54 ± 0.94
- 7.88 ± 0.41
, = 2.8 ± 0.45




















Units: a *.„ = 104 1 - mol' = ΙΟ
c KD = nmol/1
The kinetic constants kass and kdiss were calculated with the ΒΙΑ
evaluation 2.1 software, from the association and dissociation
phases on the sensorgram obtained by Surface Plasmon Resonance.
Several concentrations of each antibody (3B7, 1D7 and 3H1) in
the range of 30—220 nmol/1, bound to different immobilized apoli-
poprotein E (human apolipoprotein E3, recombinant apolipoprotein
E2, apolipoprotein E3 and apolipoprotein E4). &ass is the mean of
two values obtained by two methods (results). The equilibrium
dissociation constant KD is the report kdiss/kass.
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Tab. 2 VLDL protein and apolipoprotein E content after enrich-






















After incubation of the VLDL with the different apolipoprotein
E isoforms (human apolipoprotein E3, recombinant apolipoprot-
ein E2, apolipoprotein E3 and apolipoprotein E4), the amount
of total proteins and the amount of apolipoprotein E were mea-
sured.
nant proteins and with human apolipoprotein E3. The
different recombinant apolipoproteins E (recombinant
apolipoprotein E2, recombinant apolipoprotein E3 and
recombinant apolipoprotein E4) were equally efficient
in association with VLDL that does not contain apolipo-
protein E. Nevertheless, the ability of the recombinant
proteins to associate to apolipoprotein E-deficient
VLDL was less efficient than human plasma apolipo-
protein E3 (tab. 2). After association, the molar ratio
apolipoprotein E : apolipoprotein B48 in VLDL com-
plex was estimated to be 0.6 : 1 for recombinant apoli-
poprotein E2 and recombinant apolipoprotein E3 and
1 : 1 for recombinant apolipoprotein E4. Each apolipo-
protein E-VLDL complex was used in competition with
125I-labelled LDL for binding to the LDL receptor of
J774 cells. Each VLDL particle competed efficiently
(fig. 4), except for the recombinant apolipoprotein E2
complex and apolipoprotein E deficient VLDL, as ex-
pected.
140 -r
1 2 0 · -
10 20
Competitor concentration [mg/1]
Fig. 4 Competition of [125I]LDL with human plasma and recom-
binant apolipoprotein Ε enriched apolipoprotein Ε deficient VLDL
using the J774 macrophage cell line. Competition was performed
with human LDL (—^—), apolipoprotein Ε deficient-VLDL
(—·—), recombinant apolipoprotein E2-VLDL (—A·-), recombi-
nant apolipoprotein E3-VLDL (·-*—), recombinant apolipoprotein
E4-VLDL (..-··..).
Discussion
Expression of human apolipoprotein E was achieved by
using plasmid pARHS2, a very stable expression vector
containing the parB locus. The parB locus mediates
plasmid stabilization by post segregational killing of
plasmid free cells (26). After wopropyl- -Z)-thiogalacto-
pyranoside induction 100% of the cells still carried the
pARHS2 plasmid containing the apolipoprotein E
cDNA. This result indicates a high stability even when
expression occurs.
Production was also achieved with the pRSETB plas-
mid, which showed a high instability in E. coli. The
reasons for this instability are not clear because apolipo-
protein E was not toxic for cells and we did not observe
cell lysis during culture, as described by Vogel et al.
(27). These authors used an expression vector containing
the XPL promoter regulated by the thermolabile cl re-
pressor. Their system led to a cellular lysis associated
with an intracellular accumulation of apolipoprotein E,
followed by a proteolytic destruction of apolipoprotein
E 30 min after the induction. This cellular lysis is not a
general characteristic of the expression vector, because
this vector was used for the production of the human
growth hormone and did not show this effect (27).
Monteilhet et al. (28) described another expression sys-
tem in E. coli. Expressed sequences were under the con-
trol of the T7 promoter and allowed a production level
of 15 mg/1 of intact apolipoprotein E. Our system allows
the production of 80 mg/1 of apolipoprotein E while the
yield of purification was of about 10 mg/1 with a degree
of purtiy > 95%, as estimated by SDS-PAGE and gel
scanning. This is similar to the level of production ob-
tained with the baculovirus expression system (29), ex-
cept that our system does not allow post-translational
modifications of the protein. Purification of apolipoprot-
ein E routinely requires two chromatography steps (Hep-
arin Sepharose and Sephacryl S300, or DEAE and Hepa-
rin Sepharose). Our system allows single step purifica-
tion of fused proteins whose overall structural character-
istics are similar to those of human plasma
apolipoprotein E (20). The Ni2+-gel purification pro-
cedure is reproducible and faster than others previously
described by purifying apolipoproteins E from different
sources (27, 28).
The different experiments of characterization showed
that the fusion-peptide did not interfere in the ability of
the apolipoprotein E isoforms to bind to antibodies and
to LDL receptor. The three monoclonal antibodies bind
to the different apolipoprotein E isoforms with high af-
finity. Recombinant apolipoproteins E are somewhat less
immunoreactive with the three antibodies than is puri-
fied plasma apolipoprotein E, but the equilibrium disso-
ciation constants (KO) of the three antibodies with the
three recombinant isoforms are similar, and comparable
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to that of human plasma apolipoprotein E3 (within 2
orders of magnitude). Thus, the presence of the Mr
40 000 fusion-peptide did not significantly affect the ac-
cessibility of the three epitopes. Our results can be com-
pared to those obtained recently by Raffai' et al. (30),
who examined by RIA and Surface Plasmon Resonance
the immunoreactivity of three monoclonal antibodies
(3H1, 1D7 and 2E8) with different variants of apolipo-
protein E that were defective in LDL receptor binding
capability. The authors described that all their variants
(natural or recombinant) present a strong immunoreac-
tivity with similar binding kinetics with the antibody
3H1. The equilibrium dissociation constants (KO) are in
the range of 2.4 nmol/1 for natural apolipoprotein E3 and
5.4 nmol/1 for natural apolipoprotein E2 (Arg158 —» Cys).
Our results are consistent with these. They show that the
KO constants are between 2.0 nmol/1 for plasma apolipo-
protein E3 and 3.6 nmol/1 for recombinant apolipoprot-
ein E3. Though the epitope of 1D7 is in the LDL recep-
tor-binding domain, Riffai' et al. show that apolipoprot-
ein E2 (Arg158 —»· Cys) presents a normal 1D7 reactivity
(KO =28 nmol/1), as compared to apolipoprotein E3
(KO =19 nmol/1). Moreover, their recombinant variants,
which present mutations in the receptor binding domain,
clearly exhibit a lower capability to bind to 1D7 anti-
body than apolipoprotein E3 (KO = 60 nmol/1 and 73
nmol/1). Our recombinant proteins show close reactivity
to those of natural variants, with KO of recombinant
apolipoprotein E3 = 19.5 nmol/1, KO of recombinant
apolipoprotein E2 = 16.5 nmol/1 andKO of recombinant
apolipoprotein E4 = 19.3 nmol/1. The differences ob-
served between our different isoforms are minor com-
pared to that existing with recombinant variants pre-
senting real conformation changes.
Previously we have shown that the association of recom-
binant apolipoprotein E3 and E4 with lipids showed the
same level of incorporation of the recombinant apolipo-
protein E isoforms in di-myristoyl-phosphatidyl-cho-
line particles and, using circular dichroism, the propor-
tion of α helix, β sheets and random coil was similar
among the different apolipoproteins E in complexes
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